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Abstract
Motivation: The somatic mutations in the pathways that drive cancer development tend to be mutually
exclusive across tumors, providing a signal for distinguishing driver mutations from a larger number of
random passenger mutations. This mutual exclusivity signal can be confounded by high and highly vari-
able mutation rates across a cohort of samples. Current statistical tests for exclusivity that incorporate
both per-gene and per-sample mutational frequencies are computationally expensive and have limited
precision.
Results: We formulate a weighted exact test for assessing the significance of mutational exclusivity in an
arbitrary number of mutational events. Our test conditions on the number of samples with a mutation as
well as per-event, per-sample mutation probabilities. We provide a recursive formula to compute p-values
for the weighted test exactly as well as a highly accurate and efficient saddlepoint approximation of the
test. We use our test to approximate a commonly used permutation test for exclusivity that conditions
on per-event, per-sample mutation frequencies. However, our test is more efficient and it recovers more
significant results than the permutation test. We use our Weighted Exclusivity Test (WExT) software
to analyze hundreds of colorectal and endometrial samples from The Cancer Genome Atlas, which are
two cancer types that often have extremely high mutation rates. On both cancer types, the weighted
test identifies sets of mutually exclusive mutations in cancer genes with fewer false positives than earlier
approaches.
Availability: See http://compbio.cs.brown.edu/projects/wext for software.
Contact: braphael@cs.brown.edu
1 Introduction
A key challenge in cancer genomics is distinguishing the small number of somatic mutations that drive
cancer from the vast majority of mutations that accumulate randomly. The ability to distinguish these
driver mutations from the random passenger mutations may lead to better understanding of cancer
biology and personalized therapies customized to a tumor’s mutational profile. However, large scale
cancer sequencing efforts such as The Cancer Genome Atlas (TCGA) [29, 31, 30] and the International
Cancer Genome Consortium (ICGC) have shown that many driver mutations are rare across patient
cohorts and thus distinguishing the driver mutations from the passengers by their frequency of occurrence
is a difficult problem.
Driver mutations are hypothesized to group into a small number of pathways or hallmarks [10], and
this hypothesis is a widely accepted explanation for the observed mutational heterogeneity of cancer [35].
Thus, researchers have developed methods to identify combinations of mutations using varying levels of
prior knowledge, from pathway databases [37, 24, 27] to protein-protein interaction networks [33, 7, 26,
17].
∗To whom correspondence should be addressed.
1
ar
X
iv
:1
60
7.
02
44
7v
1 
 [q
-b
io.
QM
]  8
 Ju
l 2
01
6
Because prior knowledge of pathways and interactions is often noisy or unavailable, de novo methods
that do not use prior information are advantageous. The vast number of possible combinations of mutated
genes makes complete de novo discovery of combinations computationally and statistically intractable.
However, a number of methods [22, 34, 7, 16, 28, 8, 4, 18, 13, 14] use the observation that mutations
within the same pathway are often mutually exclusive across tumors [32, 39]. These methods differ in
how they score mutual exclusivity and in how they identify the best scoring set(s) of mutations.
The first type of score for mutual exclusivity is a combinatorial score, such as the scores employed in
[22, 34, 16]. For example, in the Dendrix algorithm [34], the score for a set M of mutational events is the
difference between the number of samples with a mutation in M (coverage) and the number of mutations
in M occurring in more than one sample (coverage overlap). The advantage of a combinatorial score is
that it is easy to compute, but it was observed by [18] and others that the score is often biased towards
sets with frequently mutated genes.
The second type of score for mutual exclusivity is a statistical score [7, 19, 28, 8, 18, 13, 4, 14]. A
particularly useful statistical score for exclusivity is based on the exact distribution that conditions on
the observed number of mutated samples in each gene [18, 4]. For a pair of mutations, such a test is a
one-sided Fisher’s exact test for independence [19, 18, 4]. For more than two genes, [18] generalized the
exact test to multi-dimensional contingency tables. They introduced the CoMEt algorithm that computes
a generalization of Fisher’s exact test for event sets of any size using either an exact tail enumeration
algorithm or an approximation. They showed that conditioning on the number of mutations in each
events reduces bias towards frequently mutated events compared to combinatorial scores.
Statistical scores that condition only on mutation frequencies do not account for the variation in
mutation rate among tumors. It has been observed that the number of mutations in a tumor can vary
over several orders of magnitude (e.g., see [35, 15, 25]). For example, colorectal tumors with microsatel-
lite stability have a median of 66 nonsynonymous mutations, but colorectal tumors with microsatellite
instability have a median of 777 mutations [35]. Another example is from [31], who classified a subset of
TCGA endometrial cancers as ultramutated or hypermutated.
Another useful statistical test for mutual exclusivity conditions on both the number of mutated sam-
ples in each event and the number of mutated events in each sample [7, 13]. Since computing this
distribution exactly is not computationally efficient, permutation tests are used. The permutation tests,
which compare observed results to a number of samples (∼104) drawn from a null distribution, are more
tractable than computing the p-value exactly on genome-scale data, but the significance of the score is
directly limited by the number of permutations. MEMo [7] computes the significance of the coverage
(number of mutated samples) of M using this permutational distribution for sets of any size k. MEM-
Cover [13] computes the significance of the exclusivity of pairs to search for exclusivity within, between,
and across cancer types. Both MEMo and MEMCover restrict their analysis to sets of genes that inter-
act in a protein-interaction network. WeSME [14], which appeared while this paper was under review,
computes the significance of exclusivity of pairs of genes with a less expensive approximation to the
permutational distribution. To our knowledge, there is no method for quickly computing the significance
of mutual exclusivity conditioned on both the observed number of mutations per event and number of
mutations per sample.
1.1 Contributions
We introduce a weighted test for mutual exclusivity that conditions on the frequency of each mutational
event in a set M and also incorporates the probability that each event is mutated in each sample. Our
test was inspired by a model derived by [20], who computed the significance of the overlap between two
sets of genes weights by gene length. We introduce the weighted exclusivity test to approximate the
fixed gene and sample frequency permutation test quickly and accurately by estimating the mutation
probabilities from the null distribution of the permutation test. We present a recursive formula for
computing the p-value of this test exactly and derive a saddlepoint approximation for arbitrarily sized
groups of genes. We show that the saddlepoint approximation is both a fast and accurate approximation
of the permutational distribution. We also demonstrate that the saddlepoint approximation can be used
to rapidly compute the CoMEt statistical test, which is a special case of the weighted test where the
mutation probabilities for a given gene are the same in each sample.
We use our Weighted Exclusivity Test (WExT) software to identify sets of exclusive mutations in
hundreds of colorectal and endometrial cancers. Cancer of these types often have extremely high mutation
rates (e.g., see [35]), which makes them difficult to analyze when conditioning only on the number of
mutated samples per event. However, our weighted statistical test allows us to effectively condition
on the number of mutated genes per sample, and we identify exclusive patterns of mutations in these
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Test p-value Conditioning Algorithms
Row (R) exclusivity ΦR Event frequencies Tail enumeration (CoMEt),
saddlepoint approximation
Row-column (RC) exclusivity ΦRC Event and sample frequencies Permutations
Weighted-row (WR) exclusivity ΦWR Event frequencies and per-event, Recursive formula,
per-sample weights (W ) saddlepoint approximation
Table 1: Three tests for mutual exclusivity, the values that are fixed in each test, and differ-
ent algorithms for computing the p-values associated with the tests. Boldface entries indicate
contributions by this manuscript.
cancers that were missed by earlier approaches. We find that the weighted test identifies more biologically
interesting sets than CoMEt [18]. We expect that the weighted test for mutual exclusivity will prove
useful for many cancer types where defects in DNA damage or environmental exposures, e.g., ultraviolet
light, lead to very high mutation rates in some samples.
2 Methods
We introduce a new weighted test for mutual exclusivity that incorporates per-event, per-sample mutation
probabilities, and we describe how to use particular instances of our test to approximate commonly used
tests for mutual exclusivity, which we refer to as the row exclusivity (R-exclusivity) and row-column
exclusivity (RC-exclusivity) tests.
First, in Section 2.2, we describe the R-exclusivity and RC-exclusivity tests. Next, in Section 2.3, we
introduce our new weighted test for mutual exclusivity, which we call the weighted-row exclusivity (WR-
exclusivity) test , that incorporates event and sample mutation frequencies without using permutations.
In Section 2.4, we describe how to approximate the R-exclusivity and RC-exclusivity tests with the WR-
exclusivity test. Then, in Section 2.5, we provide a recursive formula for computing the WR-exclusivity
p-value exactly, and we derive a fast and accurate saddlepoint approximation for the WR-exclusivity
p-value. Finally, in Sections 2.6, we describe how we search for exclusive sets, and in Section 2.7, we
describe our WExT software.
We summarize the tests and our contributions in this paper in Table 1.
2.1 Notation
We observe the presence or absence of mutational events across a collection of samples. The presence
of an event may reflect a variety of genomic (e.g., the canonical BRAF V600E mutation or deletions in
CDKN2A), proteomic, and/or epigenomic alterations. In this work, we analyze single nucleotide variants
and small insertion/deletions (indels) by gene. For the clarity of exposition, we will describe these events
at the gene level, but our weighted test can accommodate a broader class of mutational events.
Let {gi}mi=1 be a set of m genes and {sj}nj=1 be a set of n samples. For each sample, we observe the
presence of one or more mutations in each gene, and we record the presence or absence of mutations in
a per-gene, per-sample binary mutation matrix A ∈ {0, 1}m×n, where A = [aij ] with aij = 1 if gene gi is
mutated in sample sj and aij = 0 otherwise.
Let M ⊆ {gi}mi=1 be a set of k genes. The gene set M has co-occurring mutations in sample sj if
multiple genes are mutated in that sample, i.e., there exist distinct gi, g` ∈ M such that aij = 1 and
a`j = 1. Alternatively, the gene set M has a mutually exclusive mutation in sample sj if one and only one
gene is mutated in that sample, i.e., there exists g` ∈M such that a`j = 1 and aij = 0 for gi ∈M \ {g`}.
Our goal is to identify sets of genes with statistically significant numbers of mutually exclusive mutations.
Let ri =
∑n
j=1 aij be the number of samples with mutations in gi, let cj =
∑m
i=1 aij be the number
of genes with mutations in sj , let zM be the number of samples with co-occurring mutations in M , and
let tM be the number of samples with mutually exclusive mutations in M .
For any mutation matrix B, let B(M) be the submatrix of B with rows corresponding to the gene
set M , and let tB(M) be the number of mutually exclusive mutations in B(M). We will use tM = tA(M).
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2.2 Permutation tests for mutual exclusivity
We describe two different permutation tests for mutual exclusivity. First, the row-exclusivity (R-exclusivity)
test finds the probability ΦR(M) of observing at least tM mutually exclusive mutations in a gene set
M given that each gi ∈ M is mutated in ri samples. We describe this test as the row-exclusivity test
because it conditions on the row sums of the mutation matrix.
Formally, we define ΩR to be the set of mutation matrices with same row sums as A. Let ER ={
B ∈ ΩR : tB(M) ≥ tM
}
be the set of mutation matrices with at least tM mutually exclusive mutations
in M . Then
ΦR(M) =
|ER|
|ΩR| (1)
is the p-value of the R-exclusivity test.
Since the R-exclusivity test only conditions on the row sums of A, we can consider each row of A
independently. This implies that to compute ΦR(M), we use only the rows corresponding to M . Thus, for
k = 2, the p-value ΦR(M) is equal to the p-value from the one-sided Fisher’s exact test, which computes
the tail probability by summing the hypergeometric probability of 2 × 2 contingency tables with fixed
margins. The hypergeometric probability of each contingency table is the proportion of matrices in
ΩR that give a contingency table with those margins. Note also that, when k = 2, the probability of
observing tM or more mutually exclusive mutations is equal to the probability of observing zM or more
co-occurring mutations. [18] generalized this test to k > 2 genes as part of the CoMEt algorithm.
The row-column-exclusivity (RC-exclusivity) test finds the probability ΦRC(M) of observing at least
tM mutually exclusive mutations in a gene set M given that each gi ∈ M is mutated in ri samples
and each sj is mutated in cj genes. We describe this test as the row-column-exclusivity test because it
conditions on the row and column sums of the mutation matrix.
Formally, we define ΩRC to be the set of mutation matrices with the same row and column sums
as A. Let ERC =
{
B ∈ ΩRC : tB(M) ≥ tM
}
be the set of mutation matrices with at least tM mutually
exclusive mutations in M . Then
ΦRC(M) =
|ERC|
|ΩRC| (2)
is the p-value of the RC-exclusivity test. Since ΩRC depends on the row and column sums of A, we
cannot consider the rows of A, or even A(M), independently.
The RC-exclusivity test is related to the co-occurrence and mutual exclusivity tests used in [7] and
[13, 14] with a few key differences. First, [7] use coverage (i.e., tM + zM ) instead of exclusivity as the
test statistic, while [13, 14] limit to pairs of genes. Second, both [7] and [13] use permutation tests that
sample matrices from ΩRC, so their p-values are limited by the number of draws (e.g., both use 10
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permutations).
2.3 Weighted exact test for mutual exclusivity
We introduce a new weighted test for mutual exclusivity. The weighted-row-exclusivity (WR-exclusivity)
test finds the probability ΦWR(M) of observing at least tM mutually exclusive mutations in a gene set
M given that gi ∈ M is mutated in ri samples and a per-gene, per-sample mutation probability matrix
W that prescribes weights with the presence or absence of individual mutations. We describe this test
as the weighted-row-exclusivity test because it conditions on the row sums of the mutation matrix and
a probability weight matrix.
For our model, we assume that {Xij}nj=1 is a set of mutually independent Bernoulli trials for each
gene gi with success probabilities W = [wij ], i.e.,
Pr(Xij = `) =
{
wij , if ` = 1,
1− wij , if ` = 0,
(3)
where wij is the probability that gene gi is mutated in sample sj . Let TM,j be a random variable
with TM,j = 1 if sj has a mutually exclusive mutation in a gene set M and TM,j = 0 otherwise.
Therefore, Yi =
∑n
j=1 Xij is a Poisson binomial distributed variable for the number of mutations in
gi and TM =
∑n
j=1 TM,j is a test statistic for mutual exclusivity indicating the number of mutually
exclusive mutations in M . We want to find the tail probability (commonly referred to as the p-value) of
observing at least tM mutually exclusive mutations in M given that gi is mutated in ri samples. The
WR-exclusivity p-value ΦWR(M) is the probability of observing at least tM mutations in a gene set M
under this model with
ΦWR(M) = Pr(TM ≥ tM | YM = rM ) (4)
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where YM = [Yi]i∈M and rM = [ri]i∈M .
Note that, for any gene gi, the assumption that Yi = ri implies that
n∑
j=1
wij =
n∑
j=1
E[Xij ] = E
[
n∑
j=1
Xij
]
= E[Yi] = ri (5)
by the definitions of {Xij}nj=1 and Yi.
2.4 Approximating the permutation tests with the weighted exclusivity
test
Each of the sets ΩR and ΩRC underlying the R-exclusivity and RC-exclusivity tests, respectively, deter-
mines a per-gene, per-sample weight matrix W = [wij ] by considering the probability wij of observing a
mutation in gene gi in sample sj , i.e.,
W =
1
|Ω|
∑
B∈Ω
B (6)
where Ω ∈ {ΩR,ΩRC}. Since both ΩR and ΩRC fix the number of mutated samples per gene, the weight
matrix W in (6) with Ω ∈ {ΩR,ΩRC} satisfies (5). We define WR to be the weight matrix with Ω = ΩR
and WRC to be the weight matrix with Ω = ΩRC.
For the R-exclusivity test, each row of B ∈ ΩR can be considered separately, so (6) for the set ΩR is
given by WR = [wij ], with wij =
ri
n
.
However, for the RC-exclusivity test, each row B ∈ ΩRC cannot be considered separately, so, to the
best of our knowledge, there is no closed-form expression for (6) for the set ΩRC. Therefore, we generate
an empirical weight matrix WNRC = [wij ] for ΩRC by drawing N matrices Ω
N
RC uniformly at random from
ΩRC and computing (6) with Ω
N
RC instead of ΩRC. We assume that there is a nonzero probability that
any gene can be mutated in any sample, and thus set wij =
1
2N
when no mutation in gene gi is observed
in sample sj in Ω
N
RC.
Estimating WNRC in this way gives an accurate approximation of ΦRC(M) using relatively small values
of N .
2.5 Computing the weighted exclusivity test
Our weighted test for mutual exclusivity requires computing the tail probability in (4), which can be
computationally expensive. We compute the tail probability using two different strategies: a recursive
formula and a saddlepoint approximation.
2.5.1 Recursive formula for the weighted exclusivity test
We present a recursive formula for computing the tail probability in (4) exactly for sets M of any size k.
Assuming that {Yi}mi=1 are mutually independent, we can write (4) as
ΦWR(M) =
Pr(TM ≥ tM , YM = rM )∏
i∈M Pr(Yi = ri)
. (7)
Without loss of generality, let M = {1, . . . , k}. We first find the joint probability in the numerator of
(7) using a recursive formula, where Pr(TM ≥ tM , YM = rM ) = F (tM , r1, . . . , rk, n) is computed by the
recurrence relation
F (t, x1, . . . , xk, j) =∑
pi∈{0,1}k
k∏
i=1
qijpiiF (wpi(t), ypi1(x1), . . . , ypik (xk), j − 1),
(8)
where
qij` =
{
pij if ` = 1,
0 otherwise,
wpi(t) =
{
t− 1 if ∑ki=1 pii = 1,
t otherwise,
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and
y`(x) =
{
x− 1 if ` = 1,
x otherwise.
The base cases for (8) are
F (t, x1, . . . , xk, j) =

1, if t = x1 = · · · = xk = j = 0,
0, if min{t, x1, . . . , xk, j} < 0,
t >
∑k
i=1 xi, or
maxki=1 xi > n.
(9)
We then find the marginal probabilities in the denominator of (7) using dynamic programming, which
is a standard method for computing the Poisson-Binomial probability mass function [12].
2.5.2 Saddlepoint approximation for the weighted exclusivity test
We derive a saddlepoint approximation [6] for computing the tail probability in (4). This approach
is inspired by [20], who derive a saddlepoint approximation for an enrichment test for differentially
expressed genes in Gene Ontology categories weighted by gene lengths. The saddlepoint approximation
is specifically designed to provide a quick and accurate approximation of the tail probability. We present
the key equation in (10) and provide a fuller derivation for k = 3 in the supplement. The saddlepoint
approximation is given by
Pr(TM ≥ tM | YM = rM ) ≈ 1− Φ(w˜)− φ(w˜)
(
1
w˜
− 1
u˜
)
, (10)
where Φ and φ are, in this setting, the cumulative distribution and density functions, respectively, of the
standard normal distribution, and w˜ and u˜ are defined as follows.
Without loss of generality, letM = {1, . . . , k}. First, for λ ∈ Rk+1, letMYM ,TM (λ) = E[e
∑
i∈M λiYi+λk+1TM ]
be the joint moment generating function of {Yi}i∈M and TM , and let KYM ,TM (λ) = logMYM ,TM (λ) be
the corresponding joint cumulant generating function. Similarly, let MYi(λ) = E[eλiYi ] be the mo-
ment generating function of Yi, and let KYi(λ) = logMYi(λ) be the corresponding cumulant generating
function.
Next, let K′YM ,TM (λ) and K′′YM ,TM (λ) be the gradient vector and Hessian matrix, respectively, of
KY,T (λ), and let K′Yi(λ) and K′′Yi(λ) be the gradient vector and Hessian matrix, respectively, of KYi(λ).
Finally, define w˜ by
w˜ =
√
2 sgn (y˜k+1)
√∑
i∈M
KYi(xˆi)−KYM ,TM (y˜)− y˜T (xˆ− x˜) (11)
and u˜ by
u˜ = 2 sinh
(
y˜k+1
2
)√√√√ ∣∣∣K′′YM ,TM (y˜)∣∣∣∏
i∈M K′′Yi(xˆi)
, (12)
where x˜ =
(
r1, . . . , rk, tM − 12
)
and y˜ = (y˜1, . . . , y˜k+1) with y˜ the unique solution for K′YM ,TM (y˜) = x˜
and (10) undefined if y˜k+1 = 0, and xˆ = (xˆ1, . . . , xˆk, 0) with xˆi the unique solution for K′Yi(xˆi) = ri.
2.6 Searching for sets of mutually exclusive mutations
Our goal is to identify sets M of genes with significantly exclusive mutations, i.e., extremely small
p-values ΦWR(M). There has been a considerable amount of work on methods for optimizing scores
for mutually exclusive mutations, including Markov chain Monte Carlo methods [34, 18], integer linear
programs [16, 40], greedy algorithms [4], and others. These methods have been shown to be able to
search datasets of many hundreds of mutation events for mutually exclusive mutations. Many of these
methods can be modified to use our weighted exclusivity test to identify the most significant sets.
Since our focus is a statistical test for exclusivity, we instead enumerate all sets M of k genes satisfying
the following basic criteria and test them with the R-exclusivity, RC-exclusivity, and WR-exclusivity tests:
1. The number tM of samples with mutually exclusive mutations must be larger than the number zM
of samples with co-occurring mutations, i.e., tM > zM .
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2. Each gene gi ∈M must have at least one exclusive mutation.
We use the Benjamini-Hochberg procedure [5] to control the false discovery rate (FDR). We examine the
subset of genes in each dataset with a minimum mutation frequency so that we can enumerate and test
all combinations of genes of a certain size in a reasonable amount of time.
2.7 Implementation
We implemented the recursive formula for the WR-exclusivity test in Python and C, and we im-
plemented the saddlepoint approximation for the WR-exclusivity test in Python using the NumPy
and SciPy numerical libraries. We implemented the RC-exclusivity test in Python, and we used a
bipartite double edge swap algorithm (see [23, 9]) that has been shown empirically to sample uni-
formly from ΩRC. Our code, along with commands and data for reproducing the results and fig-
ures in this paper, is available as the Weighted Exclusivity Test (WExT) software package at http:
//compbio.cs.brown.edu/projects/wext.
3 Results
We compare the results of the WR-exclusivity test to both the R-exclusivity and RC-exclusivity tests
on real data. In general, we can choose any weights to compute WR-exclusivity, but, in this paper,
we specifically consider weights to allow us to approximate the R-exclusivity and RC-exclusivity tests.
We use WExT to discover mutually exclusive sets of mutations in thyroid, colorectal, and endometrial
cancers, restricting our analysis to mutations at the gene level.
The rest of this section is organized as follows. In Section 3.1, we describe the data used in our exper-
iments. In Section 3.2, we compare the tail enumeration and saddlepoint approximation algorithms for
computing the R-exclusivity p-values ΦR(M), and we show that the saddlepoint approximation provides
a fast and accurate approximation for ΦR(M). In Section 3.3, we compare the results of the recursive
and saddlepoint approximation algorithms for computing the WR-exclusivity p-values ΦWR(M) with the
results of the RC-exclusivity test, and we show that ΦWR(M) is an accurate approximation of ΦRC(M)
using either the recursive or saddlepoint approximation algorithms. In Section 3.4, we show that ΦWR(M)
provides an accurate approximation of ΦRC(M) even with coarser estimates of the weight matrix W .
Finally, in Sections 3.5 and 3.6, we present the results of the WR-exclusivity test on thyroid, colorectal,
and endometrial cancers.
3.1 Data
We analyzed non-synonymous single nucleotide variants (SNVs) and small insertions or deletions (indels)
in 224 colorectal (COADREAD) [29], 402 papillary thyroid carcinoma (THCA) [30], and 248 uterine cor-
pus endometrial carcinoma (UCEC) [31] samples from The Cancer Genome Atlas (TCGA). We analyzed
the mutations in the COADREAD and UCEC samples from the TCGA Pan-Cancer project [36] by
downloading the mutations in Mutation Annotation Format (MAF) from Synapse [1]. We downloaded
the mutations in THCA from Firehose [2]. We restricted our analysis to non-synonymous mutations,
ignoring mutations classified as “Silent”, “Intron”, “3’UTR”, “5’UTR”, “IGR”, “lincRNA”, and “RNA”.
We also downloaded lists of hypermutator samples for COADREAD and UCEC. We created a list of 35
hypermutator samples in COADREAD listed in [29] in their Supplementary Table 3, and 82 hypermuta-
tor samples in UCEC listed by [31] as samples labeled “POLE OR MSI” in their Supplementary Datafile
S1.1. We restrict our analysis to genes mutated in at least 20, 5, and 30 samples in the COADREAD,
THCA, and UCEC datasets, analyzing 76, 30, and 62 genes in each dataset, respectively.
In general, COADREAD samples have the most mutated genes (median: 78.5), with COADREAD
hypermutators with mutations in at least an order of magnitude more genes than non-hypermutators
(median for hypermutators: 797; median for non-hypermutators: 69). THCA samples have the fewest
mutated genes per sample (median: 12), with no hypermutators, while UCEC has more mutated genes
per sample (median: 57.5) with UCEC hypermutators mutated in approximately an order of magnitude
more genes than non-hypermutators (median hypermutators: 355; median non-hypermutators: 43.5).
See Supplementary Figure S1.
For each dataset, we estimated the weights WNRC using the permutation procedure described in
Section 2.4 using N = 103 permutations. We show the weights for each dataset in Figure 1.
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Figure 1: The weights WN estimated by sampling N = 10
3 permuted matrices on the THCA,
COADREAD, and UCEC datasets. Samples (x-axis) are sorted by the number of mutated
genes in increasing order from left to right, with hypermutators (right) separated from non-
hypermutators (left) with a dashed line in COADREAD and UCEC. Genes (y-axis) are sorted
by the number of mutated samples in increasing order from top to bottom.
3.2 Comparison of methods for computing the R-exclusivity test on
real data
First, we investigated the accuracy and speed of the saddlepoint approximation of the R-exclusivity p-
value ΦR(M). We enumerated triples according to the procedure described in Section 2.6 in the THCA,
COADREAD, and UCEC datasets, and computed ΦR(M) exactly using the CoMEt software from [18]
as well as approximately using the saddlepoint approximation with WR given in Section 2.4.
Supplementary Figure S2 shows a comparison of the p-values and runtimes given by the two meth-
ods, where the weights for the WR-exclusivity test are uniform across samples. On these datasets, the
saddlepoint approximation is an extremely accurate approximation of the tail enumeration procedure
(ρ2 = 0.995). Additionally, while the median runtimes of the two algorithms are similar, the tail enumer-
ation procedure is much slower for sets with co-occurring mutations while the saddlepoint approximation
is largely unaffected. We expect the discrepancy between runtimes to grow for gene sets of larger sizes.
3.3 Comparison of methods for computing the WR-exclusivity test on
real data
Next, we compared the results of methods for computing WR-exclusivity test with weights WNRC the RC-
exclusivity test on pairs of genes from the THCA, COADREAD, and UCEC datasets. We chose pairs
instead of triples because of the prohibitive cost of computing the recursive formula for ΦWR(M). We
used N = 104 permutations to compute the ΦRC(M), and also included the tail enumeration procedure
for ΦR(M) as a control.
Table 2 shows that the results of WR-exclusivity test – computed either with the recursive formula or
the saddlepoint approximation – are strongly correlated with the RC-exclusivity test (Figure 2(b)). The
results of the R-exclusivity test are more weakly correlated with the RC-exclusivity test (Figure 2(a)),
showing that conditioning on the number of mutations in each sample changes the distribution of mutually
exclusive mutations. This discrepancy remains when we restrict to gene sets M with ΦRC(M) ≥ 10−4,
i.e., sets of genes for which the empirical permutational distribution finds at least one mutually exclusive
mutation in M .
The WR-exclusivity p-values computed exactly and with the saddlepoint approximation are highly
correlated (Figure 2(c)), with a Pearson’s correlation coefficient of 0.996 for all p. For smaller p-values
with ΦWR(M) < 10
−4 from either the recursive formula or the saddlepoint approximation, the correlation
increases to 0.9999.
The runtime to compute ΦWR using the recursive formula varies widely because pairs with co-
occurring mutations require more computation, but the runtime of the saddlepoint approximation is
more consistent. As a result, testing all pairs with the recursive formula requires approximately 2 hours,
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Pairs ΦR (CoMEt) ΦWR (recursive) ΦWR (saddlepoint)
All 0.71291 0.99816 0.99481
ΦRC(M) ≥ 10−4 0.65376 0.99811 0.99404
Table 2: Pearson’s correlation coefficient ρ2 of p-values of pairs of genes from the THCA,
COADREAD, and UCEC datasets using the tail enumeration R-exclusivity p-values ΦR(M),
RC-exclusivity p-values ΦRC(M), and the recursive formula and saddlepoint approximations of
the WR-exclusivity p-values ΦWR(M) using weights WR. The correlations were computed for
two sets of pairs of genes: p-values for 5,014 pairs (all) and 4,926 pairs (ΦRC(M) ≥ 10−4).
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Figure 2: Comparison of p-values and runtimes of different tests on THCA, COADREAD, and
UCEC pairs. (a-b) Scatter plots comparing the RC-exclusivity test with N = 104 permutations
against (a) the R-exclusivity test and (b) the WR-exclusivity test (recursive) with weights WNRC .
(c) The WR-exclusivity (recursive) p-values versus the WR-exclusivity (saddlepoint) p-values
with weights WNRC . (d) Boxplots of the runtimes for computing the weighted test with the
recusive formula (red) and with the saddlepoint approximation (blue) for each pair of genes in
the datasets.
but testing the same pairs with the saddlepoint approximation requires approximately 30 seconds. Note
that the runtime does not include generating the weights WNRC , which requires several minutes.
3.4 Approximating the RC-exclusivity test with the WR-exclusivity
test
We compared the saddlepoint approximation of the WR-exclusivity test to the RC-exclusivity test using
gene triples from the COADREAD dataset, again using the R-exclusivity test as a control. We computed
ΦRC(M) with N = 10
6 permutations. We computed the saddlepoint approximation for ΦWR(M) using
WNRC with N = 10
3 draws from ΩRC, which is three orders of magnitude fewer than the number of
permutations than we used to compute ΦRC(M). The p-values ΦR(M) and ΦRC(M) are weakly correlated
in the tail (ρ2 = 0.67 for ΦRC(M) < 0.001; see Figure 3a). In contrast, the ΦWR(M) (saddlepoint)
p-values provide an accurate approximation of the ΦRC(M) p-values. The RC-exclusivity and WR-
exclusivity p-values are highly correlated in the tail (ρ2 = 0.948 for ΦRC(M) < 0.001; see Figure 3b).
Moreover, ΦWR(M) is an accurate estimate of ΦRC(M) to within one or more digits for most triples
and within an order of magnitude for all triples. Furthermore, despite the much smaller number of
permutations used to generate WNRC , ΦWR(M) provides smaller p-values than ΦRC(M) with a greater
number of significant predictions, and is much faster than the permutation test.
3.5 Mutually exclusive mutations in thyroid carcinomas
We computed the WR-exclusivity p-values for all triples of genes that were each mutated in at least 5
of the 402 thyroid carcinomas in the THCA dataset. The WR-exclusivity test identifies 48 triples with
significantly exclusive mutations (FDR < 0.001), while the R-exclusivity test identifies 38 triples (FDR
< 0.001).
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Figure 3: Comparison of the R-exclusivity test (left, y-axis) and the saddlepoint approximation
of the WR-exclusivity test with weights WNRC estimated from N = 10
3 permutations (right, y-
axis) to the R-exclusivity test (x-axis) on triples from the COADREAD dataset. The saddlepoint
approximation uses weights WNRC estimated from N = 10
3 permutations, while the RC-exclusivity
p-values were computed with N = 106 permutations.
The top 25 ranked triples by both tests are identical, which is not surprising since THCA samples
have low mutation rates compared to most cancer types (see [35] and Section 3.1). In addition, the
p-values for the top ranked triples are all within a few orders of magnitude, demonstrating that the two
tests are very similar on this dataset.
Supplementary Table S1 shows the top triples, which include many known thyroid cancer genes. The
top five triples include seven genes, five of which are well-known cancer genes with known roles in thyroid
cancer [30]: BRAF, HRAS, NRAS, EIF1AX, and ATM. The other two genes are BDP1 and TG, both
of which may play a role in cancer. [38] describe a role for BDP1 in AKT signaling, which was also
noted in TCGA thyroid publication [30]), although BDP1 is greater than 11,000 amino acids in length,
so it may also accumulate many passenger mutations. TG is the thyroglobulin gene, and is used as a
tumor marker in papillary thyroid carcinoma [3], which is the same subtype of thyroid cancer analyzed
in TCGA.
3.6 Mutually exclusive mutations in colorectal cancers and endome-
trial carcinomas
We expect that the difference between the R-exclusivity and WR-exclusivity tests would be more pro-
nounced on cancer types with higher and highly variable mutation rates. Thus, we computed p-values
on triples of genes from colorectal cancers (COADREAD) and endometrial carcinomas (UCEC). We find
that the WR-exclusivity test predicts more biologically interesting triples than the R-exclusivity test.
The WR-exclusivity test identifies 5,290 and 6,835 triples (many of which overlap) with significantly mu-
tually exclusive mutations (FDR < 0.001) in the 224 COADREAD and 248 UCEC samples, respectively.
In contrast, the R-exclusivity test computes 4 and 130 triples, respectively, with significantly mutually
exclusive mutations (FDR < 0.001).
Compared to the R-exclusivity test results, the highest ranked triples by the WR-exclusivity test
include fewer long genes that tend to accumulate random, passenger mutations – especially in samples
with high mutation rates (Tables 3 and 4).
On COADREAD, the WR-exclusivity test identifies ten different genes in the five most significant
triples (Table 3). Nine of these genes are well-known cancer genes – BRAF, KRAS, NRAS, ACV2RA,
PIK3CA, TP53, ATM, TGFBR2, and ARID1A – while the tenth gene (ABCA12 ) is known to have an
association with colorectal cancers [11]. The R-exclusivity test results are similar – two of the top five
triples identified by the WR-exclusivity test are in the top five triples identified by the R-exclusivity
test – but the R-exclusivity test does not identify ARID1A, TGFBR2, KRAS, or NRAS. Further, the
three additional genes identified by the R-exclusivity – APC, FAT2, and WDFY3 – are all in the top
600 longest genes in the human genome (at least 9,560 amino acids). While mutations in APC are
well-known to play a role in colorectal cancers, there is currently little evidence for the roles of FAT2 or
WDFY3 in cancer, and it is likely that these long genes have accumulated many passenger mutations,
particularly in hypermutated samples. Also of note is the fact that the number of hypermutator samples
that contain mutations in the top triples from the WR-exclusivity test are not appreciably different from
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ΦR rank ΦWR rank Triple M ΦR(M) ΦWR(M) Hypermutator mutations
1 2 ACVR2A, PIK3CA, TP53 2.65 · 10−7 2.54 · 10−18 31
2 32 APC, BRAF, PRDM2 5.44 · 10−7 2.30 · 10−13 33
2 33 APC, BRAF, WDFY3 5.44 · 10−7 2.43 · 10−13 32
4 3 ATM, PIK3CA, TP53 5.87 · 10−7 1.15 · 10−17 24
5 81 APC, BRAF, FAT2 1.93 · 10−6 6.48 · 10−12 35
6 1 BRAF, KRAS, NRAS 2.50 · 10−6 9.95 · 10−19 26
1 2 ACVR2A, PIK3CA, TP53 2.65 · 10−7 2.54 · 10−18 31
4 3 ATM, PIK3CA, TP53 5.87 · 10−7 1.15 · 10−17 24
10 4 ARID1A, TGFBR2, TP53 5.89 · 10−6 1.76 · 10−16 29
9 5 ABCA12, TGFBR2, TP53 4.29 · 10−6 1.83 · 10−16 28
Table 3: Five most significant triples identified by the R-exclusivity (upper 5) and WR-exclusivity
(lower 5) tests on the COADREAD dataset. Genes in bold are among 600 longest genes (at least
9,560 amino acids).
ΦR rank ΦWR rank Triple M ΦR(M) ΦWR(M) Hypermutator mutations
1 20 CACNA1E, PTEN, TP53 3.11 · 10−12 5.71 · 10−30 77
2 21 LAMA2, PTEN, TP53 4.13 · 10−12 8.05 · 10−30 77
3 29 PTEN, RYR2, TP53 4.60 · 10−12 4.85 · 10−29 78
4 28 NBEA, PTEN, TP53 8.40 · 10−12 3.32 · 10−29 76
5 39 FAT4, PTEN, TP53 1.23 · 10−11 3.0 · 10−28 75
22 1 CTNNB1, RPL22, TP53 2.11 · 10−10 1.20 · 10−41 47
44 2 CTNNB1, KRAS, TP53 3.05 · 10−9 1.10 · 10−37 48
55 3 CTNNB1, MLL4, TP53 4.26 · 10−8 5.78 · 10−36 42
57 4 CTCF, CTNNB1, TP53 4.84 · 10−8 3.29 · 10−35 43
60 5 CTNNB1, RYR1, TP53 1.14 · 10−7 9.51 · 10−35 40
Table 4: Five most significant triples identified by the R-exclusivity (top 5) and WR-exclusivity
(bottom 5) tests on the UCEC dataset. Notation as in Table 3.
the number of hypermutator samples that contain mutations in the top triples from the R-exclusivity
test. This demonstrates that the WR-exclusivity is not systematically excluding hypermutator samples
from consideration, but rather weighting the contribution of these samples appropriately in evaluating
the significance of mutual exclusivity.
On UCEC, the differences between the R-exclusivity and WR-exclusivity tests are even more pro-
nounced. The WR-exclusivity test identifies seven genes in the top five most significant triples (Table 4).
These include six genes with known roles in cancer – CTTNB1, TP53, RPL22, KRAS, CTCF, and MLL4
– with only one gene – RYR1 – with likely spurious mutations. In contrast, the top five triples ranked
by the R-exclusivity test include PTEN, and TP53 – two well-known cancer genes – but also five genes
with no known role in cancer that are all longer than 11,000 amino acids: CACNA1E, LAMA2, RYR2,
NBEA, and FAT4. Further, none of the top five triples identified by the WR-exclusivity test are in
the top twenty R-exclusivity triples. Finally, the R-exclusivity triples include many more mutations in
hypermutator samples (ranging from mutations in 75 to 78 of the 81 hypermutators, versus 40 to 47
for the WR-exclusivity triples). This further demonstrates how the results of the R-exclusivity test are
skewed by hypermutator samples, while the WR-exclusivity test incorporates the contribution of these
samples appropriately in evaluating the significance of mutual exclusivity.
4 Discussion
We introduce a weighted exact test for the mutual exclusivity of mutations in cancer. We use this test
to approximate the permutational test for exclusivity where the number of mutations in each event and
each sample are fixed. To do so, we estimate per-event, per-sample mutation probabilities directly from
the permutational distribution. We derive a recursive formula and a saddlepoint approximation of the p-
value of the weighted test for event sets of any size, and we demonstrate the accuracy and efficiency of the
saddlepoint approximation on genome-scale mutation datasets. Together, these contributions allow us to
overcome the significant computational challenge of finding highly significant sets of mutually exclusive
11
mutations conditioned on both the observed number of mutations per event and per sample.
We then demonstrate the weighted test on three datasets with hundreds of samples from TCGA,
including colorectal and endometrial cancers that have high variability in the number of mutations per
sample. The weighted test identifies sets of mutually exclusive mutations including known cancer genes
in each dataset, and its results include many fewer long genes and mutations in hypermutator samples
than do the results of the generalization of Fisher’s exact test from CoMEt [18].
There are several avenues for improving analyses with the weighted test. First, while we restricted our
study to non-synonymous SNVs and indels, one should also test mutual exclusivity between other types
of aberrations, such as copy number aberrations and gene fusions. We searched for mutually exclusive
mutations by enumerating sets containing the most mutated genes, but the weighted test could easily
be used in existing algorithms for optimizing mutual exclusivity scores (e.g., the MCMC from [34], the
greedy approach from [4]) or to search for multiple sets simultaneously (e.g., from [18]). We estimated
the per-event, per-sample mutation probability weights directly from the permutational distribution, but
we also anticipate alternative methods for setting the weights that incorporate different event or sample
attributes, such as gene length, to further reduce the number of false positives.
The weighted test may be of broader interest beyond searching for mutually exclusive mutations,
both in other areas of computational biology and other disciplines. For example, statistical tests of
“presence-absence” matrices with fixed row and column sums are a common tool in ecology for looking
at species-associations, but can be computationally prohibitive (e.g., [21]). The weighted exact test
presented here may offer a fast, alternative approach for computing the significance of associations with
high accuracy.
5 Acknowledgments
The authors would like to acknowledge [20] for inspiring this work, and Uri Keich for generously helping
us run their code and providing comments on our manuscript. This work is supported by US National
Institutes of Health (NIH) grants R01HG005690, R01HG007069 and R01CA180776 to B.J.R. M.D.M.L.
is supported by NSF fellowship GRFP DGE 0228243. B.J.R. is supported by a Career Award at the
Scientific Interface from the Burroughs Wellcome Fund, an Alfred P. Sloan Research Fellowship and an
NSF CAREER Award (CCF-1053753).
References
[1] https://doi.org/10.7303/syn1710680.4.
[2] http://gdac.broadinstitute.org/runs/stddata__2016_01_28/data/THCA/20160128/gdac.
broadinstitute.org_THCA.Mutation_Packager_Calls.Level_3.2016012800.0.0.tar.gz.
[3] http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/62800.
[4] O¨zgu¨n Babur, Mithat Go¨nen, Bu¨lent Arman Aksoy, Nikolaus Schultz, Giovanni Ciriello, et al.
Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic
alterations. Genome biology, 16:45, 2015.
[5] Y Benjamini and Y Hochberg. Controlling the false discovery rate: a practical and powerful approach
to multiple testing. Journal of the Royal Statistical Society Series B (Methodological), 57:289–300,
1995.
[6] Ronald W Butler. Saddlepoint approximations with applications, volume 22. Cambridge University
Press, 2007.
[7] Giovanni Ciriello, Ethan Cerami, Chris Sander, and Nikolaus Schultz. Mutual exclusivity analysis
identifies oncogenic network modules. Genome research, 22(2):398–406, 2012.
[8] Simona Constantinescu, Ewa Szczurek, Pejman Mohammadi, Jo¨rg Rahnenfu¨hrer, and Niko Beeren-
winkel. TiMEx: a waiting time model for mutually exclusive cancer alterations. Bioinformatics
(Oxford, England), 2015.
[9] Andrea Gobbi, Francesco Iorio, Kevin J Dawson, David C Wedge, David Tamborero, et al. Fast
randomization of large genomic datasets while preserving alteration counts. Bioinformatics (Oxford,
England), 30(17):i617–23, 2014.
[10] Douglas Hanahan and Robert A Weinberg. Hallmarks of cancer: the next generation. Cell,
144(5):646–674, 2011.
12
[11] I Hlavata, B Mohelnikova-Duchonova, R Vaclavikova, V Liska, P Pitule, P Novak, et al. The role of
ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis, 27(2):187–
196, 2012.
[12] Yili Hong. On computing the distribution function for the Poisson binomial distribution. Compu-
tational Statistics & Data Analysis, pages 41–51, 2013.
[13] Yoo-Ah Kim, Dong-Yeon Cho, Phuong Dao, and Teresa M Przytycka. MEMCover: integrated
analysis of mutual exclusivity and functional network reveals dysregulated pathways across multiple
cancer types. Bioinformatics (Oxford, England), 31(12):i284–92, 2015.
[14] Yoo-Ah Kim, Sanna Madan, and Teresa M Przytycka. Wesme: Uncovering mutual exclusivity of
cancer drivers and beyond. Bioinformatics (Oxford, England), page To appear, 2016.
[15] Michael S Lawrence, Petar Stojanov, Paz Polak, Gregory V Kryukov, Kristian Cibulskis, et al. Muta-
tional heterogeneity in cancer and the search for new cancer-associated genes. Nature, 499(7457):214–
218, 2013.
[16] Mark D M Leiserson, Dima Blokh, Roded Sharan, and Benjamin J Raphael. Simultaneous identifi-
cation of multiple driver pathways in cancer. PLoS Computational Biology, 9(5):e1003054, 2013.
[17] Mark D M Leiserson, Fabio Vandin, Hsin-Ta Wu, Jason R Dobson, Jonathan V Eldridge, et al.
Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and
protein complexes. Nature genetics, 47(2):106–114, 2015.
[18] Mark D M Leiserson, Hsin-Ta Wu, Fabio Vandin, and Benjamin J Raphael. CoMEt: a statistical
approach to identify combinations of mutually exclusive alterations in cancer. Genome biology,
16(1):160, 2015.
[19] Timothy J Ley, Christopher Miller, Li Ding, Benjamin J Raphael, Andrew J Mungall, et al. Genomic
and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. NEJM, 368(22):2059–2074,
2013.
[20] David Manescu and Uri Keich. A Symmetric Length-Aware Enrichment Test. RECOMB, pages
224–242, 2015.
[21] I Miklo´s and J Podani. Randomization of presence-absence matrices: comments and new algorithms.
Ecology, 85(1):86–92, 2004.
[22] Christopher A Miller, Stephen H Settle, Erik P Sulman, Kenneth D Aldape, and Aleksandar
Milosavljevic. Discovering functional modules by identifying recurrent and mutually exclusive mu-
tational patterns in tumors. BMC medical genomics, 4:34, 2011.
[23] Ron Milo, Nadav Kashtan, Shalev Itzkovitz, Mark EJ Newman, and Uri Alon. On the uniform
generation of random graphs with prescribed degree sequences. arXiv preprint cond-mat/0312028,
2003.
[24] Vamsi K Mootha, Cecilia M Lindgren, Karl-Fredrik Eriksson, Aravind Subramanian, Smita Sihag,
et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately down-
regulated in human diabetes. Nature genetics, 34(3):267–273, 2003.
[25] Steven A Roberts and Dmitry A Gordenin. Hypermutation in human cancer genomes: footprints
and mechanisms. Nature Reviews Cancer, 14(12):786–800, 2014.
[26] Matthew Ruffalo, Mehmet Koyutu¨rk, and Roded Sharan. Network-Based Integration of Disparate
Omic Data To Identify ”Silent Players” in Cancer. PLoS computational biology, 11(12):e1004595,
2015.
[27] Aravind Subramanian, Pablo Tamayo, Vamsi K Mootha, Sayan Mukherjee, Benjamin L Ebert,
et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide
expression profiles. Proceedings of the National Academy of Sciences of the United States of America,
102(43):15545–15550, 2005.
[28] Ewa Szczurek and Niko Beerenwinkel. Modeling mutual exclusivity of cancer mutations. PLoS
computational biology, 10(3):e1003503, 2014.
[29] The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of human
colon and rectal cancer. Nature, 487(7407):330–337, 2012.
[30] The Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary
thyroid carcinoma. Cell, 159(3):676–690, 2014.
13
[31] The Cancer Genome Atlas Research Network, Cyriac Kandoth, Nikolaus Schultz, Andrew D Cher-
niack, Rehan Akbani, et al. Integrated genomic characterization of endometrial carcinoma. Nature,
497(7447):67–73, 2013.
[32] Roman K Thomas, Alissa C Baker, Ralph M Debiasi, Wendy Winckler, Thomas Laframboise, et al.
High-throughput oncogene mutation profiling in human cancer. Nature genetics, 39(3):347–351,
2007.
[33] Fabio Vandin, Eli Upfal, and Benjamin J Raphael. Algorithms for detecting significantly mutated
pathways in cancer. Journal of computational biology : a journal of computational molecular cell
biology, 18(3):507–522, 2011.
[34] Fabio Vandin, Eli Upfal, and Benjamin J Raphael. De novo discovery of mutated driver pathways
in cancer. Genome research, 22(2):375–385, 2012.
[35] Bert Vogelstein, Nickolas Papadopoulos, Victor E Velculescu, Shibin Zhou, Luis A Diaz, et al.
Cancer genome landscapes. Science, 339(6127):1546–1558, 2013.
[36] John N Weinstein, Eric A Collisson, Gordon B Mills, Kenna R Mills Shaw, Brad A Ozenberger,
et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genetics, 45(10):1113–1120,
2013.
[37] Michael C Wendl, John W Wallis, Ling Lin, Cyriac Kandoth, Elaine R Mardis, et al. PathScan:
a tool for discerning mutational significance in groups of putative cancer genes. Bioinformatics
(Oxford, England), 27(12):1595–1602, 2011.
[38] Annette Woiwode, Sandra A S Johnson, Shuping Zhong, Cheng Zhang, Robert G Roeder, et al.
PTEN represses RNA polymerase III-dependent transcription by targeting the TFIIIB complex.
Molecular and cellular biology, 28(12):4204–4214, 2008.
[39] Chen-Hsiang Yeang, Frank McCormick, and Arnold Levine. Combinatorial patterns of somatic gene
mutations in cancer. FASEB journal : official publication of the Federation of American Societies
for Experimental Biology, 22(8):2605–2622, 2008.
[40] Junhua Zhang, Ling-Yun Wu, Xiang-Sun Zhang, and Shihua Zhang. Discovery of co-occurring driver
pathways in cancer. BMC bioinformatics, 15:271, 2014.
14
Supplement for A Weighted Exact Test for
Mutually Exclusive Mutations in Cancer
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S1 Introduction
In Section S2 of the supplement, we provide a partial derivation of the sad-
dlepoint approximation for the WR-exclusivity p-value. In Section S3 of the
supplement, we include additional figures and tables from the experiments
in the manuscript, including
• the distributions of sample mutation frequencies for different cancer
types,
• a comparison of the R-exclusivity test and the WR-exclusivity test
with a weights given by the R-exclusivity test sample space ΩR, and
• the top triples found by the R-exclusivity test and the WR-exclusivity
test on thyroid cancer (THCA) with weights given by the RC-exclusivity
test sample space ΩRC.
S2 Derivation of the saddlepoint approximation
In this section, we derive a saddlepoint approximation for the WR-exclusivity
p-value for a set M of k events. Our approach applies to arbitrary sets M
of arbitrary size k ≥ 2, but this derivation considers k = 3 for the ease of
presentation.
Our approach is inspired by [3], who derive a saddlepoint approximation
for a weighted enrichment test for differentially expressed genes in Gene
Ontology categories, and it follows the approach of [1] in greater detail.
1
As described in the text of the manuscript, for our model, we assume
that {Xij}nj=1 is a set of mutually independent Bernoulli trials for each gene
gi with success probabilities W = [wij ], i.e.,
Pr(Xij = `) =
{
wij , if ` = 1,
1− wij , if ` = 0,
(1)
where wij is the probability that gene gi is mutated in sample sj . Let TM,j
be a random variable with TM,j = 1 if sj has a mutually exclusive mutation
in a gene set M and TM,j = 0 otherwise. Therefore, Yi =
∑n
j=1Xij is a
Poisson binomial distributed variable for the number of mutations in gi and
TM =
∑n
j=1 TM,j is a test statistic for mutual exclusivity indicating the
number of mutually exclusive mutations in M . We want to find the tail
probability (commonly referred to as the p-value) of observing at least tM
mutually exclusive mutations in M given that gi is mutated in ri samples.
The WR-exclusivity p-value ΦWR(M) is the probability of observing at least
tM mutations in a gene set M under this model with
ΦWR(M) = Pr(TM ≥ tM | YM = rM ) (2)
where YM = [Yi]i∈M and rM = [ri]i∈M .
The saddlepoint approximation is given by
Pr(TM ≥ tM | YM = rM ) ≈ 1− Φ(w˜)− φ(w˜)
(
1
w˜
− 1
u˜
)
, (3)
where Φ and φ are, in this setting, the cumulative distribution and density
functions, respectively, of the standard normal distribution, and w˜ and u˜
are defined as follows.
Without loss of generality, let M = {1, . . . , k}. First, for λ ∈ Rk+1,
let MYM ,TM (λ) = E[e
∑
i∈M λiYi+λk+1TM ] be the joint moment generating
function of {Yi}i∈M and TM , and let KYM ,TM (λ) = logMYM ,TM (λ) be the
corresponding joint cumulant generating function.
2
By the mutual independence of {Yi}i∈M , we have
KYM ,TM (λ)
= logE[eλ1Y1+λ2Y2+λ3Y3+λ4TM ]
= logE[eλ1
∑
j X1,j+λ2
∑
j X2,j+λ3
∑
j X3,j+λ4
∑
j TM,j ]
= logE[e
∑
j λ1X1,j+λ2X2,j+λ3X3,j+λ4TM,j ]
= log
n∏
j=1
E[eλ1X1,j+λ2X2,j+λ3X3,j+λ4TM,j ]
=
n∑
j=1
logE[eλ1X1,j+λ2X2,j+λ3X3,j+λ4TM,j ].
(4)
Note that TM,j can be written in terms of {Xij}i∈M . In this case, we have
TM,j = X1j(1−X2j)(1−X3j)
+ (1−X1j)X2j(1−X3j) + (1−X1j)(1−X2j)X3j .
(5)
Since {Xij} are mutually independent and since the expected value of a
Bernoulli random variable is equal to its success probability, we have
KYM ,TM (λ) =
n∑
j=1
logL
(j)
YM ,TM
(λ), (6)
where
L
(j)
YM ,TM
(λ)
= E[eλ1X1,j+λ2X2,j+λ3X3,j+λ4TM,j ]
= (1− w1,j)(1− w2,j)(1− w3,j) + eλ1+λ4w1,j(1− w2,j)(1− w3,j)
+ eλ2+λ4(1− w1,j)w2,j(1− w3,j) + eλ3+λ4(1− w1,j)(1− w2,j)w3,j
+ eλ1+λ2w1,jw2,j(1− w3,j) + eλ1+λ3w1,j(1− w2,j)w3,j
+ eλ2+λ3(1− w1,j)w2,jw3,j + eλ1+λ2+λ3w1,jw2,jw3,j .
(7)
Each of the above terms corresponds to one of the 2k binary assignments
for {Xij}i∈M , e.g., the term (1 − w1,j)(1 − w2,j)(1 − w3,j) corresponds to
assignments X1j = X2j = X3j = 0. For the simplicity of notation, let
L(j)(λ) = L
(j)
YM ,TM
(λ) for the rest of the derivation.
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Similarly, let MYi(λ) = E[eλiYi ] be the moment generating function of
Yi, and let KYi(λ) = logMYi(λ) be the corresponding cumulant generating
function. The derivations for these quantities are similar.
Next, let K′YM ,TM (λ) be the gradient vector of KYM ,TM (λ). For example,
we see that
∂
∂λ1
KYM ,TM (λ) =
n∑
j=1
L
(j)
λ1
(λ)
L(j)(λ)
, (8)
where
L
(j)
λ1
=
∂
∂λ1
L
(j)
YM ,TM
(λ)
= eλ1+λ4w1,j(1− w2,j)(1− w3,j) + eλ1+λ2w1,jw2,j(1− w3,j)
+ eλ1+λ3w1,j(1− w2,j)w3,j + eλ1+λ2+λ3w1,jw2,jw3,j .
(9)
The derivations for the remaining entries of K′YM ,TM (λ) are similar.
Furthermore, let K′′YM ,TM (λ) be the Hessian matrix of KYM ,TM (λ). For
example, we see that
∂2
∂λ1∂λ2
KYM ,TM (λ) =
n∑
j=1
L
(j)
λ1λ2
L(j)
− L
(j)
λ1
L
(j)
λ2(
L(j)
)2 , (10)
where L
(j)
λ1
and L
(j)
λ2
were already derived for the derivation of K′YM ,TM and
L
(j)
λ1λ2
=
∂2
∂λ1∂λ2
L
(j)
Y (λ)
= eλ1+λ2w1,jw2,j(1− w3,j) + eλ1+λ2+λ3w1,jw2,jw3,j .
(11)
The derivations for the remaining entries of K′′YM ,TM (λ) are similar.
Finally, define w˜ by
w˜ =
√
2 sgn (y˜k+1)
√∑
i∈M
KYi(xˆi)−KYM ,TM (y˜)− y˜T (xˆ− x˜) (12)
and u˜ by
u˜ = 2 sinh
(
y˜k+1
2
)√√√√ ∣∣∣K′′YM ,TM (y˜)∣∣∣∏
i∈M K′′Yi(xˆi)
, (13)
where x˜ =
(
r1, . . . , rk, tM − 12
)
and y˜ = (y˜1, . . . , y˜k+1) with y˜ the unique
solution for K′YM ,TM (y˜) = x˜ and (3) undefined if y˜k+1 = 0, and xˆ =
(xˆ1, . . . , xˆk, 0) with xˆi the unique solution for K′Yi(xˆi) = ri.
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Note that, in general, K′YM ,TM (y˜) = x˜ is a system of k + 1 nonlin-
ear equations, and K′Yi(xˆi) is a sequence of k nonlinear equations. A root
finder, e.g., the MINPACK routine HYBRJ [4], can solve these systems of
equations when given expressions for the gradient vector K′YM ,TM (λ) and the
Hessian matrix K′′YM ,TM (λ); the MINPACK routine HYBRD approximatesK′′YM ,TM (λ). Various wrappers for HYBRJ and HYBRD exist in various lan-
guages, including SciPy’s Python wrapper [2], which we used in our code.
S3 Supplemental figures and tables
Figure S1 compares the number of mutated genes per sample in thyroid
cancers (THCA), colorectal cancers (COADREAD), and endometrial carci-
nomas (UCEC), demonstrating high mutation rates in several COADREAD
and UCEC samples and high mutational variability in COADREAD and
UCEC data.
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Figure S1: Boxplot of the number of mutated genes per sample in the THCA,
COADREAD, and UCEC datasets. The COADREAD and UCEC samples
are further broken down into hypermutators (blue) and non-hypermutators
(red).
Figure S2 shows a comparison of the p-values and runtimes given by
the recusive formula and the saddlepoint approximation methods. On these
datasets, the saddlepoint approximation is an extremely accurate approxi-
mation of the tail enumeration procedure (ρ2 = 0.995). Additionally, while
the median runtimes of the two algorithms are similar, the tail enumeration
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procedure is much slower for sets with co-occurring mutations while the
saddlepoint approximation is largely unaffected. We expect the discrepancy
between runtimes to grow for gene sets of larger sizes. Also, the saddlepoint
approximation can be optimized when approximating the R-exclusivity test
because each row of the corresponding weight matrix has identical entries,
but we did not do so here.
Figure S2: Comparison of the tail enumeration and saddlepoint approxima-
tion algorithms for computing the R-exclusivity p-value ΦR(M) on triples in
THCA, COADREAD, and UCEC. (left) Scatter plot comparing the p-values
given by the tail enumeration algorithm (x-axis) versus the saddlepoint ap-
proximation (y-axis). (right) Distribution of the runtime (in seconds) re-
quired to compute each method on a single triple.
Table S1 shows the five most significant triples identified by the R-
exclusivity and WR-exclusivity tests on thyroid cancer (THCA).
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ΦR rank ΦWR rank Triple M ΦR(M) ΦWR(M)
1 1 BRAF, HRAS, NRAS 1.79 · 10−22 1.79 · 10−27
2 2 BRAF, EIF1AX, NRAS 2.27 · 10−16 2.73 · 10−20
3 3 BDP1, BRAF, NRAS 2.70 · 10−14 6.01 · 10−18
4 4 BRAF, NRAS, TG 3.51 · 10−13 5.62 · 10−17
5 5 BRAF, MUC5B, NRAS 6.58 · 10−13 1.90 · 10−16
Table S1: Five most significant triples identified by the R-exclusivity and
WR-exclusivity tests on the THCA dataset. Genes in bold are among the
600 longest genes (at least 9,560 amino acids). Seven triples tie for the fifth
smallest R-exclusivity p-value, so we indicate the triple with the smallest
WR-exclusivity p-value in the table.
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